JP2012508734A - Ｂａｃｅ阻害剤としての置換イソインドール類及びそれらの使用 - Google Patents

Ｂａｃｅ阻害剤としての置換イソインドール類及びそれらの使用 Download PDF

Info

Publication number
JP2012508734A
JP2012508734A JP2011536289A JP2011536289A JP2012508734A JP 2012508734 A JP2012508734 A JP 2012508734A JP 2011536289 A JP2011536289 A JP 2011536289A JP 2011536289 A JP2011536289 A JP 2011536289A JP 2012508734 A JP2012508734 A JP 2012508734A
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
fluoro
pyridyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011536289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508734A5 (cg-RX-API-DMAC7.html
Inventor
イェルク・ホーレンツ
ソフィア・カールストレム
カリン・コルモディン
ヨハン・リンドストレム
ラースロ・ラコス
ディディエ・ロッティッシ
ペーテル・セーデルマン
ブリット−マリエ・スヴァーン
ベルク シュテファン・フォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42170158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012508734(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2012508734A publication Critical patent/JP2012508734A/ja
Publication of JP2012508734A5 publication Critical patent/JP2012508734A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2011536289A 2008-11-14 2009-11-13 Ｂａｃｅ阻害剤としての置換イソインドール類及びそれらの使用 Pending JP2012508734A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11463408P 2008-11-14 2008-11-14
US61/114,634 2008-11-14
US13976708P 2008-12-22 2008-12-22
US61/139,767 2008-12-22
US22165309P 2009-06-30 2009-06-30
US61/221,653 2009-06-30
PCT/SE2009/051295 WO2010056196A1 (en) 2008-11-14 2009-11-13 New compounds 578

Publications (2)

Publication Number Publication Date
JP2012508734A true JP2012508734A (ja) 2012-04-12
JP2012508734A5 JP2012508734A5 (cg-RX-API-DMAC7.html) 2012-12-20

Family

ID=42170158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536289A Pending JP2012508734A (ja) 2008-11-14 2009-11-13 Ｂａｃｅ阻害剤としての置換イソインドール類及びそれらの使用

Country Status (24)

Country Link
US (2) US8030500B2 (cg-RX-API-DMAC7.html)
EP (1) EP2367814A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012508734A (cg-RX-API-DMAC7.html)
KR (1) KR20110091540A (cg-RX-API-DMAC7.html)
CN (1) CN102282140A (cg-RX-API-DMAC7.html)
AR (1) AR074341A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009314664A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921879A2 (cg-RX-API-DMAC7.html)
CA (1) CA2743938A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011001098A1 (cg-RX-API-DMAC7.html)
CO (1) CO6362004A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110255A (cg-RX-API-DMAC7.html)
CU (1) CU20110106A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000138A (cg-RX-API-DMAC7.html)
EA (1) EA201190020A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011051A (cg-RX-API-DMAC7.html)
IL (1) IL212590A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011004918A (cg-RX-API-DMAC7.html)
NI (1) NI201100099A (cg-RX-API-DMAC7.html)
PE (1) PE20110875A1 (cg-RX-API-DMAC7.html)
TW (1) TW201020244A (cg-RX-API-DMAC7.html)
UY (1) UY32241A (cg-RX-API-DMAC7.html)
WO (1) WO2010056196A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201104396B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101052122B1 (ko) 2005-10-25 2011-07-26 시오노기세야쿠 가부시키가이샤 아미노디히드로티아진 유도체
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
MX2009011498A (es) 2007-04-24 2009-11-10 Shionogi & Co Derivados de aminodihidrotiazina sustituida con un grupo ciclico.
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
AU2009258496B8 (en) 2008-06-13 2014-06-26 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
US20110281894A1 (en) * 2010-05-12 2011-11-17 Astrazeneca Ab Hemifumarate salt
EP2601197B1 (en) 2010-08-05 2014-06-25 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
WO2012057247A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
US20120165346A1 (en) * 2010-12-22 2012-06-28 Astrazeneca Ab Compounds and their use as BACE inhibitors
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
WO2016160703A1 (en) 2015-03-27 2016-10-06 Harrup Mason K All-inorganic solvents for electrolytes
CN105272884B (zh) * 2015-11-02 2017-05-24 浙江大学 一种邻氰基二苯甲酮衍生物的制备方法
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149033A1 (en) * 2006-06-22 2007-12-27 Astrazeneca Ab Substituted isoindoles as bace inhibitors and their use
JP2008526966A (ja) * 2005-01-14 2008-07-24 ワイス β−セクレターゼの阻害のためのアミノ−イミダゾロン

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) * 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
AU702293B2 (en) * 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
DE4419849A1 (de) 1994-06-07 1995-12-14 Hoechst Ag Isoindolinpigmente
CA2192820C (en) 1994-06-16 2000-11-28 Yuhpyng L. Chen Pyrazolo and pyrrolopyridines
DE19516804A1 (de) 1995-05-08 1996-11-14 Hoechst Ag Isoindolinpigmente auf Basis von Aminochinoxalindionen
EP0871720A2 (en) * 1995-06-07 1998-10-21 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
US6211235B1 (en) * 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US6245769B1 (en) 1997-09-02 2001-06-12 Dupont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
EP1115874B1 (en) 1998-09-24 2009-01-07 Pharmacia & Upjohn Company LLC Alzheimer's disease secretase
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
WO2000047618A2 (en) 1999-02-10 2000-08-17 Elan Pharmaceuticals, Inc. HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
WO2000077030A1 (en) 1999-06-15 2000-12-21 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase
CN1379819A (zh) 1999-06-28 2002-11-13 俄克拉荷马州医学研究基金会 具有催化活性的重组memapsin蛋白酶及其应用方法
PT1224297E (pt) 1999-09-23 2009-08-17 Pharmacia & Upjohn Co Llc Secretase da doença de alzheimer, seus substratos app e suas utilizações
GB9924957D0 (en) 1999-10-21 1999-12-22 Smithkline Beecham Plc Novel treatment
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
CN1217920C (zh) 2000-06-30 2005-09-07 艾兰制药公司 治疗早老性痴呆的化合物
WO2002014264A2 (en) 2000-08-11 2002-02-21 The Brigham And Women's Hospital, Inc. (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
ES2282292T3 (es) 2000-09-22 2007-10-16 Wyeth Estructura cristalina de bace y usos de la misma.
CN102627609B (zh) 2003-12-15 2016-05-04 默沙东公司 杂环天冬氨酰蛋白酶抑制剂
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1732906A4 (en) 2004-03-30 2007-11-21 Merck & Co Inc 2-AMINOTHIAZONE COMPOUNDS SUITABLE AS ASPARTYL PROTEASE INHIBITORS
US20080153869A1 (en) 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
WO2006009655A1 (en) * 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
AU2005264915A1 (en) * 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US7405215B2 (en) 2004-09-21 2008-07-29 Wyeth Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
WO2006041405A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-pyrimidones and uses thereof
WO2006041404A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-compounds and uses thereof
JP2008523139A (ja) 2004-12-14 2008-07-03 アストラゼネカ・アクチエボラーグ 置換アミノピリジン類及びその使用
ZA200707896B (en) 2005-03-14 2009-07-29 High Point Pharma Llc Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
MX2007016183A (es) 2005-06-14 2008-03-10 Schering Corp Preparacion y uso de compuestos como inhibidores de proteasas.
EP1902057B1 (en) * 2005-06-14 2013-10-23 Merck Sharp & Dohme Corp. Macrocyclic heterocyclic aspartyl protease inhibitors
CA2610617A1 (en) 2005-06-14 2006-12-28 Schering Corporation The preparation and use of protease inhibitors
CN101198595A (zh) * 2005-06-14 2008-06-11 先灵公司 天冬氨酰基蛋白酶抑制剂
BRPI0612072A2 (pt) 2005-06-14 2010-10-19 Schering Corp inibidores da aspartil protease
MX2007016177A (es) 2005-06-14 2008-03-07 Schering Corp La preparacion y uso de compuestos como inhibidores de aspartil proteasas.
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
EP1896448A1 (en) * 2005-06-30 2008-03-12 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
AU2006270084B2 (en) 2005-07-18 2011-08-25 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
US7601751B2 (en) * 2005-09-01 2009-10-13 Bristol-Myers Squibb Company Indole acetic acid acyl guanidines as β-secretase inhibitors
KR101052122B1 (ko) * 2005-10-25 2011-07-26 시오노기세야쿠 가부시키가이샤 아미노디히드로티아진 유도체
AR057983A1 (es) * 2005-10-27 2008-01-09 Schering Corp Inhibidores hterociclicos de aspartil proteasas
JP2009513670A (ja) * 2005-10-31 2009-04-02 シェーリング コーポレイション アスパルチルプロテアーゼインヒビター
JP2009515950A (ja) 2005-11-15 2009-04-16 アストラゼネカ・アクチエボラーグ 新規な２−アミノピリミジン誘導体およびその使用
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
WO2007058582A1 (en) 2005-11-15 2007-05-24 Astrazeneca Ab Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use
WO2007058580A1 (en) 2005-11-15 2007-05-24 Astrazeneca Ab Novel 2-aminopyrimidinone derivatives and their use
WO2007058601A1 (en) 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
AR058381A1 (es) 2005-12-19 2008-01-30 Astrazeneca Ab Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica
US20090099217A1 (en) 2006-04-05 2009-04-16 Astex Therapeutics Ltd. 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies
TW200808751A (en) 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
WO2007146225A2 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
WO2008063114A1 (en) 2006-11-20 2008-05-29 Astrazeneca Ab Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
TW200902499A (en) * 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
WO2009005471A1 (en) 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2009005470A1 (en) * 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
US20100125081A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 574
US20100125087A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
EP2485590B1 (en) 2009-10-08 2015-01-07 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526966A (ja) * 2005-01-14 2008-07-24 ワイス β−セクレターゼの阻害のためのアミノ−イミダゾロン
WO2007149033A1 (en) * 2006-06-22 2007-12-27 Astrazeneca Ab Substituted isoindoles as bace inhibitors and their use

Also Published As

Publication number Publication date
CU20110106A7 (es) 2012-01-31
EP2367814A4 (en) 2012-07-04
CA2743938A1 (en) 2010-05-20
CN102282140A (zh) 2011-12-14
US8030500B2 (en) 2011-10-04
CR20110255A (es) 2011-07-04
MX2011004918A (es) 2011-05-30
CO6362004A2 (es) 2012-01-20
CL2011001098A1 (es) 2012-02-24
BRPI0921879A2 (pt) 2018-10-16
AU2009314664A1 (en) 2011-06-23
PE20110875A1 (es) 2012-01-11
KR20110091540A (ko) 2011-08-11
ZA201104396B (en) 2012-03-28
ECSP11011051A (es) 2011-06-30
UY32241A (es) 2010-06-30
US20100125082A1 (en) 2010-05-20
TW201020244A (en) 2010-06-01
NI201100099A (es) 2012-03-19
WO2010056196A1 (en) 2010-05-20
IL212590A0 (en) 2011-07-31
EA201190020A1 (ru) 2012-02-28
DOP2011000138A (es) 2011-06-30
US20110319426A1 (en) 2011-12-29
EP2367814A1 (en) 2011-09-28
AR074341A1 (es) 2011-01-12

Similar Documents

Publication Publication Date Title
JP2012508734A (ja) Ｂａｃｅ阻害剤としての置換イソインドール類及びそれらの使用
US20100125081A1 (en) New compounds 574
US20100125087A1 (en) New compounds 575
US20080161269A1 (en) Compounds 620
JP5189074B2 (ja) ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキシル誘導体
DK3044221T3 (en) 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ON COMPOUNDS AND THERAPEUTIC APPLICATION THEREOF
US20080176862A1 (en) New Compounds 617
US20080287460A1 (en) New compounds 835
JP2009539976A (ja) アミノイミダゾロン類、ならびに認知機能障害、アルツハイマー病、神経変性および認知症を治療するための医薬品としてのそれらの使用
US20080171771A1 (en) New Compounds 391
JP2009539975A (ja) アミノイミダゾロン類、および、認知機能障害、アルツハイマー病、神経変性および認知症を治療するための医薬品としてのそれらの使用
JP2009539973A (ja) アミノイミダゾロン類、および、認知機能障害、アルツハイマー病、神経変性および認知症を治療するための医薬品としてのそれらの使用
TW200902499A (en) New compounds
US20080051420A1 (en) New Compounds 317
WO2011002409A1 (en) 5h-pyrrolo[3,4-£>]pyrazin-7-amine derivatives inhibitors of beta-secretase
US10954232B2 (en) Pyrazole derivative as ALK5 inhibitor and uses thereof
JP2004514712A (ja) 抗炎症剤としての４，６−ジフェニルピリジン誘導体
TW201105650A (en) New compounds
US20120165346A1 (en) Compounds and their use as BACE inhibitors
HK1164846A (en) New compounds 578
CN101506162B (zh) 作为β位淀粉样前体蛋白裂解酶抑制剂的取代的异吲哚和它们的用途
CN101501040A (zh) 氨基-咪唑啉以及它们作为治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物的用途
WO2022166468A1 (zh) Bruton's酪氨酸激酶抑制剂及其应用
CN101506212A (zh) 氨基-咪唑酮及其作为治疗认知缺损、阿尔兹海默病、神经变性和痴呆的药物的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140708